106 related articles for article (PubMed ID: 8898966)
1. Physiological activation of the IgH 3' enhancer in B lineage cells is not blocked by Pax-5.
Andersson T; Neurath MF; Grant PA; Pettersson S
Eur J Immunol; 1996 Oct; 26(10):2499-507. PubMed ID: 8898966
[TBL] [Abstract][Full Text] [Related]
2. Context-dependent Pax-5 repression of a PU.1/NF-kappaB regulated reporter gene in B lineage cells.
Linderson Y; French NS; Neurath MF; Pettersson S
Gene; 2001 Jan; 262(1-2):107-14. PubMed ID: 11179673
[TBL] [Abstract][Full Text] [Related]
3. A T cell controlled molecular pathway regulating the IgH locus: CD40-mediated activation of the IgH 3' enhancer.
Grant PA; Andersson T; Neurath MF; Arulampalam V; Bauch A; Müller R; Reth M; Pettersson S
EMBO J; 1996 Dec; 15(23):6691-700. PubMed ID: 8978695
[TBL] [Abstract][Full Text] [Related]
4. The murine Ig 3' alpha enhancer is a target site with repressor function for the B cell lineage-specific transcription factor BSAP (NF-HB, S alpha-BP).
Neurath MF; Strober W; Wakatsuki Y
J Immunol; 1994 Jul; 153(2):730-42. PubMed ID: 8021508
[TBL] [Abstract][Full Text] [Related]
5. IgM receptor-mediated transactivation of the IgH 3' enhancer couples a novel Elf-1-AP-1 protein complex to the developmental control of enhancer function.
Grant PA; Thompson CB; Pettersson S
EMBO J; 1995 Sep; 14(18):4501-13. PubMed ID: 7556093
[TBL] [Abstract][Full Text] [Related]
6. Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation.
Morrison AM; Nutt SL; Thévenin C; Rolink A; Busslinger M
Semin Immunol; 1998 Apr; 10(2):133-42. PubMed ID: 9618759
[TBL] [Abstract][Full Text] [Related]
7. C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8.
Dörfler P; Busslinger M
EMBO J; 1996 Apr; 15(8):1971-82. PubMed ID: 8617244
[TBL] [Abstract][Full Text] [Related]
8. NFE, a new transcriptional activator that facilitates p50 and c-Rel-dependent IgH 3' enhancer activity.
Linderson Y; Cross D; Neurath MF; Pettersson S
Eur J Immunol; 1997 Feb; 27(2):468-75. PubMed ID: 9045919
[TBL] [Abstract][Full Text] [Related]
9. Early B-cell factor, E2A, and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter.
Sigvardsson M; Clark DR; Fitzsimmons D; Doyle M; Akerblad P; Breslin T; Bilke S; Li R; Yeamans C; Zhang G; Hagman J
Mol Cell Biol; 2002 Dec; 22(24):8539-51. PubMed ID: 12446773
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of BSAP/Pax-5 inhibits switching to IgA and enhances switching to IgE in the I.29 mu B cell line.
Qiu G; Stavnezer J
J Immunol; 1998 Sep; 161(6):2906-18. PubMed ID: 9743352
[TBL] [Abstract][Full Text] [Related]
11. Yin Yang 1 is a lipopolysaccharide-inducible activator of the murine 3' Igh enhancer, hs3.
Gordon SJ; Saleque S; Birshtein BK
J Immunol; 2003 Jun; 170(11):5549-57. PubMed ID: 12759432
[TBL] [Abstract][Full Text] [Related]
12. NF-kappa B and Oct-2 synergize to activate the human 3' Igh hs4 enhancer in B cells.
Sepulveda MA; Emelyanov AV; Birshtein BK
J Immunol; 2004 Jan; 172(2):1054-64. PubMed ID: 14707079
[TBL] [Abstract][Full Text] [Related]
13. Corecruitment of the Grg4 repressor by PU.1 is critical for Pax5-mediated repression of B-cell-specific genes.
Linderson Y; Eberhard D; Malin S; Johansson A; Busslinger M; Pettersson S
EMBO Rep; 2004 Mar; 5(3):291-6. PubMed ID: 14993928
[TBL] [Abstract][Full Text] [Related]
14. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments.
Nutt SL; Morrison AM; Dörfler P; Rolink A; Busslinger M
EMBO J; 1998 Apr; 17(8):2319-33. PubMed ID: 9545244
[TBL] [Abstract][Full Text] [Related]
15. Regulation of 3' IgH enhancers by a common set of factors, including kappa B-binding proteins.
Michaelson JS; Singh M; Snapper CM; Sha WC; Baltimore D; Birshtein BK
J Immunol; 1996 Apr; 156(8):2828-39. PubMed ID: 8609402
[TBL] [Abstract][Full Text] [Related]
16. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells.
Lin KI; Angelin-Duclos C; Kuo TC; Calame K
Mol Cell Biol; 2002 Jul; 22(13):4771-80. PubMed ID: 12052884
[TBL] [Abstract][Full Text] [Related]
17. Anti-IgM antibodies down modulate mu-enhancer activity and OTF2 levels in LPS-stimulated mouse splenic B-cells.
Chen U; Scheuermann RH; Wirth T; Gerster T; Roeder RG; Harshman K; Berger C
Nucleic Acids Res; 1991 Nov; 19(21):5981-9. PubMed ID: 1658749
[TBL] [Abstract][Full Text] [Related]
18. An NFAT-dependent enhancer is necessary for anti-IgM-mediated induction of murine CD5 expression in primary splenic B cells.
Berland R; Wortis HH
J Immunol; 1998 Jul; 161(1):277-85. PubMed ID: 9647234
[TBL] [Abstract][Full Text] [Related]
19. Temporal expression of a V(H) promoter-Cmu transgene linked to the IgH HS1,2 enhancer.
Andersson T; Furebring C; Borrebaeck CA; Pettersson S
Mol Immunol; 1999 Jan; 36(1):19-29. PubMed ID: 10369417
[TBL] [Abstract][Full Text] [Related]
20. CD86 and beta2-adrenergic receptor signaling pathways, respectively, increase Oct-2 and OCA-B Expression and binding to the 3'-IgH enhancer in B cells.
Podojil JR; Kin NW; Sanders VM
J Biol Chem; 2004 May; 279(22):23394-404. PubMed ID: 15024018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
